Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge.

Translational research : the journal of laboratory and clinical medicine - 1 Oct 2022

Shi Juan, Zheng Jian, Zhang Xiujuan, Tai Wanbo, Odle Abby E, Perlman Stanley, Du Lanying

Abstract excerpt

Multiple SARS-CoV-2 variants are identified with higher rates of transmissibility or greater disease severity. Particularly, recent emergence of Omicron variant with rapid human-to-human transmission posts new challenges to the current prevention strategies. In this study, following vaccination with an mRNA vaccine encoding SARS-CoV-2 receptor-binding domain (RBD-mRNA), we detected serum antibodies that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Viral
Share to Broadly Neutralizing Antibodies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to COVID-19

Share to Neutralization Tests

Share to SARS-CoV-2

Share to Spike Glycoprotein, Coronavirus

Share to Vaccines, Synthetic

Share to Viral Vaccines

Source

Open in PubMed Open full text

Identifiers

PMID: 35489692
DOI: 10.1016/j.trsl.2022.04.007
PMCID: PMC9045870

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge.PMID 35489692Read ↗

Neutralizing antibodies to SARS‐CoV‐2 variants of concern including Delta and Omicron in subjects receiving mRNA‐1273, BNT162b2, and Ad26.COV2.S vaccinesSemantic proximity Read ↗

mRNA-Based COVID-19 Vaccine Boosters Induce Neutralizing Immunity Against SARS-CoV-2 Omicron VariantSemantic proximity Read ↗

Universal subunit vaccine protects against multiple SARS-CoV-2 variants and SARS-CoVSemantic proximity Read ↗

An mRNA vaccine candidate for the SARS-CoV-2 Omicron variantSemantic proximity Read ↗

Effectiveness of a broad-spectrum bivalent mRNA vaccine against SARS-CoV-2 variants in preclinical studiesSemantic proximity Read ↗

Broadly neutralizing antibodies against Omicron variants of SARS-CoV-2 derived from mRNA-lipid nanoparticle-immunized miceSemantic proximity Read ↗

Omicron-specific mRNA vaccine elicits potent immune responses in mice, hamsters, and nonhuman primatesSemantic proximity Read ↗

Omicron-specific mRNA vaccine induced potent neutralizing antibody against Omicron but not other SARS-CoV-2 variantsSemantic proximity Read ↗

Preclinical evaluation of RQ3013, a broad-spectrum mRNA vaccine against SARS-CoV-2 variantsSemantic proximity Read ↗

Mucosal immunity against SARS-CoV-2 variants of concern including Omicron following vaccinationSemantic proximity Read ↗

Broadly Neutralizing Antibodies Against Omicron Variants of SARS-CoV-2 Derived from mRNA-Lipid Nanoparticle-Immunized MiceSemantic proximity Read ↗

A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.